Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2007-07-24
2007-07-24
Prouty, Rebecca E. (Department: 1652)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C424S094640, C514S012200, C536S023400, C435S069200, C435S226000
Reexamination Certificate
active
10025514
ABSTRACT:
Fusion proteins of protease inhibitors are provided, in particular fusion proteins of alpha 1-antitrypsin (AAT) and a second protease inhibitor, such as secretory leukocyte protease inhibitor (SLPI) or tissue inhibitor of metalloproteases (TIMP). Polynucleotides encoding the fusion proteins, vectors comprising such polynucleotides, and host cells containing such vectors are also provided. Methods of making the fusion proteins of the invention are also provide, as well as methods of using the fusion proteins, for example to inhibit protease activity in a biological sample or in the treatment of an individual suffering from, or at risk for, a disease or disorder involving unwanted protease activity.
REFERENCES:
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 4732973 (1988-03-01), Barr et al.
patent: 4746648 (1988-05-01), Wagnon et al.
patent: 4752576 (1988-06-01), Brake et al.
patent: 4760130 (1988-07-01), Thompson et al.
patent: 4845076 (1989-07-01), Heinzel et al.
patent: 4870008 (1989-09-01), Brake
patent: 4873316 (1989-10-01), Meade et al.
patent: 5008242 (1991-04-01), Lezdey et al.
patent: 5093316 (1992-03-01), Lezdey et al.
patent: 5217951 (1993-06-01), Lezdey et al.
patent: 5290762 (1994-03-01), Lezdey et al.
patent: 5328470 (1994-07-01), Nabel et al.
patent: 5464822 (1995-11-01), Christophers et al.
patent: 5595885 (1997-01-01), Stetler-Stevenson et al.
patent: 5633227 (1997-05-01), Muller et al.
patent: 5643752 (1997-07-01), Hawkins et al.
patent: 5780440 (1998-07-01), Lezdey et al.
patent: 5849691 (1998-12-01), Majer et al.
patent: 5851983 (1998-12-01), Sugiyama et al.
patent: 5871956 (1999-02-01), Bandyopadhyay et al.
patent: 5900400 (1999-05-01), Thompson et al.
patent: 5914392 (1999-06-01), Hawkins et al.
patent: 5985309 (1999-11-01), Edwards et al.
patent: 6017880 (2000-01-01), Eisenberg et al.
patent: 6068994 (2000-05-01), Barr
patent: 6124257 (2000-09-01), Lezdey et al.
patent: 6131566 (2000-10-01), Ashurst et al.
patent: 6136295 (2000-10-01), Edwards et al.
patent: 6143277 (2000-11-01), Ashurst et al.
patent: 6174859 (2001-01-01), Lezdey et al.
patent: RE37053 (2001-02-01), Hanes et al.
patent: 6253762 (2001-07-01), Britto
patent: 6254854 (2001-07-01), Edwards et al.
patent: 6291662 (2001-09-01), Bandyopadhyay et al.
patent: B-13288/88 (1988-09-01), None
patent: 0 073 657 (1983-03-01), None
patent: 0 073 657 (1983-03-01), None
patent: 0 264 166 (1988-04-01), None
patent: 0 283 932 (1988-09-01), None
patent: 0 404 750 (1990-12-01), None
patent: 0 648 838 (1995-04-01), None
patent: 63-267294 (1991-06-01), None
patent: WO 86/02100 (1986-04-01), None
patent: WO 86/03519 (1986-06-01), None
patent: WO 92/10575 (1992-06-01), None
patent: WO 98/51788 (1998-11-01), None
Urwin P. E. et al., Enhanced transgenic plant resistance to nemathodes by dual proteinase inhibitor constructs, Planta, 1998, 204, 472-479.
Carrell R. W. et al., Alpha1-Antitrypsin Deficiency - A Model for Conformational Diseases, N. Engl. J. Med., 2002, 346, 45-53.
Crystal, R.G. et al. (1989). “The Alpha1-Antitrypsin Gene and Its Mutations. Clinical Consequences and Strategies for Therapy,”Chest95(1):196-208.
Jeppsson, J.O. and Laurell, C.B. (1988). “The Amino Acid Substitutions of Human α1Antitrypsin M3, X and Z,”FEBS Lett.231(2):327-330.
Kwon, K.S. et al. (1994). “Single Amino Acid Substitutions of α1-Antitrypsin That Confer Enhancement in Thermal Stability,”J. Biol. Chem.269(13):9627-9631.
Luisetti, M. et al. (1990). “Alpha 1-Antitrypsin Variants Produced by Recombinant DNA: Differences in Elastase Inhibitory Activity and Resistance to Oxidant Agents,”Int. J. Tissue React.12(6):363-368.
Patterson, S.D. (1991). “Mammalian α1-Antitrypsins: Comparative Biochemistry and Genetics of the Major Plasma Serpin,”Comp. Biochem. Physiol.100B(3):439-454.
Agarwal, N. S. and Rich, D. H. (1986). “Inhibition of Cathepsin D by Substrate Analogues Containing Statine and by Analogues of Pepstatin,”J. Med. Chem.29:2519-2524.
Ausubel, F. M. et al. (2001).Current Protocols in Molecular Biology,John Wiley & Sons, Inc. 11 pages total (Table of Contents for vols. 1-4 only).
Aviles, F. X. (1993).Innovations in Proteases and Their Inhibitors,W. DeGruyter, Berlin, N.Y. total pages 5. (Table of Contents).
Baldwin, E. T. et al. (Jul. 1993). “Crystal Structures of Native and Inhibited Forms of Human Cathepsin D: Implications for Lysosomal Targeting and Drug Design,”Proc. Natl. Acad. Sci.90:6796-6800.
Banerji, J. et al. (Jul. 1983). “A Lymphocyte-Specific Cellular Enhancer is Located Downstream of the Joining Region in Immunoglobulin Heavy Chain Genes,”Cell33:729-740.
Barnes, P. J. (Feb. 2000). “Mechanisms in COPD: Differences From Asthma,”Chest117(2):10S-14S.
Barnes, P. J. (Jul. 2000). “Chronic Obstructive Pulmonary Disease,”Medical Progress343(4)269-280.
Barrett, A. J. et al. (1986). “Cysteine Proteinase Inhibitors of the Cystatin Superfamily,” Chapter 18In Proteinase Inhibitors.A. J. Barrett and G. Salvesen eds., Elsevier Science Publishers, pp. 515-568.
Beaucage, S. L. and Caruthers, M. H. (1981). “Deoxynucleoside Phosphoramidites-A New Class of Key Intermediates for Deoxypolynucleotide Synthesis,”Tetrahedron Letters22(20):1859-1862.
Bingle, L. and Tetley, T.D. (1996). “Secretory Leukoprotease Inhibitor: Partnering α1-Proteinase Inhibitor to Combat Pulmonary Inflammation,”Science Matters51:1273-1274.
Bode, W. and Huber, R. (1992). “Natural Protein Proteinase Inhibitors and Their Interaction with Proteinases,”Eur. J. Biochem.204:433-451.
Bode, W. and Huber, R. (1994). “Proteinase-Protein Inhibitor Interactions,”Fibrinolysis8 (Suppl. 1):161-171.
Bode, W. and Huber, R. (2000). “Structural Basis of The Endoproteinase-Protein Inhibitor Interaction,”Biochimica et Biophysica Acta1477:241-252.
Boone, T. C. et al. (Apr. 1990). “cDNA Cloning and Expression of a Metalloproteinase Inhibitor Related to Tissue Inhibitor of Metalloproteinases,”Proc. Natl. Acad. Sci.87:2800-2804.
Byrne, G. W. and Ruddle, F. H. (Jul. 1989). “Multiplex Gene Regulation: A Two-Tiered Approach to Transgene Regulation in Transgenic Mice,”Proc. Natl. Acad. Sci.86:5473-5477.
Calame, K. and Eaton, S. (1988). “Transcriptional Controlling Elements in the Immunoglobulin and T Cell Receptor Loci,”Adv. in Immunol.43:235-275.
Camper, S. A. and Tilghman, S. M. (1989). “Postnatal Repression of the α-Fetoprotein Gene is Enhancer Independent,”Genes&Dev.3:537-546.
Carrell, R.W. et al. (Jul. 1982). “Structure and Variation of Human α1-Antitrypsin,”Nature298:329-334.
Cawston, T. E. (1995). “Proteinases and Inhibitors,”British Medical Bulletin51(2):385-401.
Chen, S. H et al. (Apr. 1994). “Gene Therapy for Brain Tumors: Regression of Experimental Gliomas by Adenovirus-Mediated Gene TransferIn Vivo,” Proc. Natl. Acad. Sci.91:3054-3057.
Coligan, J. E. et al. (1991).Current Protocols in Immumology,John Wiley & Sons, Inc. 10 pages total. (Table of Contents of vols. 1-3 only).
Collier, I. E. et al. (May 1988). “H-ras Oncogene-transformed Human Bronchial Epithelial Cells (TBE-1) Secrete a Single Metalloprotease Capable of Degrading Basement Membrane Collagen,”The J. of Biol. Chem.263(14):6579-6587.
Docherty, A. J. P. et al. (Nov. 1985). “Sequence of Human Tissue Inhibitor of Metalloproteinases and its Identity to Erythroid-Potentiating Activity,”Nature318:66-69.
Eckman, E.A. et al. (Aug. 1999). “In VitroTransport of Active α1-Antitrypsin to the Apical Surface of Epithelia by Targeting the Polymeric Immunoglobulin Receptor,”Am. J. Respir. Cell Mol. Biol.21:246-252.
Edlund, T. et al. (Nov. 1985). “Cell-Specific Expression of the Rat Insulin Gene: Evidence for Role of Two Distinct 5′ Flanking Elements,”Science230:912-916.
Edwards, D.A. et al. (Jun. 1997)
Barr Philip J.
Gibson Helen L.
Pemberton Philip A.
Arriva Pharmaceuticals, Inc.
Heller Ehrman LLP
Prouty Rebecca E.
Walicka Malgorzata A.
LandOfFree
Multifunctional protease inhibitors and their use in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multifunctional protease inhibitors and their use in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multifunctional protease inhibitors and their use in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3735680